Phreesia, Inc. (NYSE:PHR) Given Consensus Rating of “Buy” by Brokerages

Phreesia, Inc. (NYSE:PHR) has been assigned an average recommendation of “Buy” from the eleven research firms that are covering the stock, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $32.27.

PHR has been the topic of a number of research analyst reports. Citigroup reaffirmed a “buy” rating on shares of Phreesia in a report on Wednesday, May 28th. KeyCorp upped their target price on shares of Phreesia from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Monday, July 14th. DA Davidson upgraded shares of Phreesia to a “strong-buy” rating in a report on Tuesday, July 22nd. Wall Street Zen upgraded shares of Phreesia from a “hold” rating to a “buy” rating in a report on Sunday, June 1st. Finally, Truist Financial increased their price target on Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, May 29th.

Phreesia Stock Performance

Shares of Phreesia stock opened at $26.31 on Monday. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -35.55 and a beta of 0.71. The firm’s 50-day moving average is $26.82 and its 200 day moving average is $26.41. Phreesia has a 1 year low of $17.07 and a 1 year high of $30.53. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.95 and a quick ratio of 1.95.

Phreesia (NYSE:PHR) last issued its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.06. The firm had revenue of $115.94 million for the quarter, compared to the consensus estimate of $115.00 million. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The business’s revenue was up 14.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. Sell-side analysts anticipate that Phreesia will post -1.1 EPS for the current fiscal year.

Insider Activity at Phreesia

In other Phreesia news, SVP David Linetsky sold 23,729 shares of the company’s stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $28.50, for a total value of $676,276.50. Following the transaction, the senior vice president directly owned 193,510 shares in the company, valued at $5,515,035. This represents a 10.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Evan Roberts sold 1,892 shares of the company’s stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $26.89, for a total transaction of $50,875.88. Following the completion of the transaction, the chief operating officer owned 772,915 shares in the company, valued at $20,783,684.35. This represents a 0.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,804 shares of company stock worth $1,510,733 in the last three months. 5.50% of the stock is owned by insiders.

Institutional Trading of Phreesia

Hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Phreesia by 108.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock valued at $67,606,000 after purchasing an additional 1,377,904 shares in the last quarter. American Century Companies Inc. boosted its stake in Phreesia by 3,741.9% in the first quarter. American Century Companies Inc. now owns 983,440 shares of the company’s stock valued at $25,137,000 after acquiring an additional 957,842 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its stake in Phreesia by 133.6% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 1,271,832 shares of the company’s stock valued at $31,999,000 after acquiring an additional 727,384 shares in the last quarter. Greenhouse Funds LLLP boosted its position in shares of Phreesia by 27.9% in the 4th quarter. Greenhouse Funds LLLP now owns 2,873,892 shares of the company’s stock worth $72,307,000 after purchasing an additional 626,579 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Phreesia in the 1st quarter worth $14,206,000. Institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.